<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Causes and treatment of refractory edema in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Causes and treatment of refractory edema in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Causes and treatment of refractory edema in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            D Craig Brater, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David H Ellison, MD, FASN, FAHA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Emmett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Generalized edema can occur in a variety of disorders, including heart failure, cirrhosis (where ascites is usually most prominent), and the nephrotic syndrome; significant edema is not always present in chronic kidney disease (CKD), where extracellular fluid volume expansion is more typically manifested by hypertension, but CKD can produce resistance to diuretic treatment. When edema is massive, and the excess fluid accumulation is widely distributed, the patient is said to have anasarca.
        </p>
        <p>
         Edematous patients generally respond to the combination of dietary sodium restriction, treatment of the underlying disease process, and diuretic therapy, usually with a loop diuretic. However, some patients are resistant to typical doses of diuretics.
        </p>
        <p>
         The treatment of refractory edema in adults is reviewed here. The initial therapy of edema, treatment of the different major edematous states, the clinical manifestations and diagnosis of edema in adults, and the evaluation and management of edema in children are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6884.html" rel="external">
          "General principles of the treatment of edema in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3512.html" rel="external">
          "Use of diuretics in patients with heart failure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1256.html" rel="external">
          "Ascites in adults with cirrhosis: Initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1258.html" rel="external">
          "Ascites in adults with cirrhosis: Diuretic-resistant ascites"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3044.html" rel="external">
          "Pathophysiology and treatment of edema in adults with the nephrotic syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6878.html" rel="external">
          "Clinical manifestations and evaluation of edema in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6104.html" rel="external">
          "Evaluation and management of edema in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1857844085">
         <span class="h1">
          DEFINITION OF REFRACTORY EDEMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Refractory edema is defined as edema that is refractory to typically effective doses of loop diuretics [
         <a href="#rid1">
          1
         </a>
         ]. While this definition appears to be straightforward, it is often difficult to determine the optimal extracellular fluid volume status for an edematous patient, as this process involves substantial clinical judgement and shared decision-making.
        </p>
        <p>
         The following discussion will describe principles underlying the treatment of refractory edema; a following section will present specific recommendations for such patients.
        </p>
        <p class="headingAnchor" id="H3673969508">
         <span class="h1">
          CAUSES OF REFRACTORY EDEMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of factors can account for persistent sodium and water retention, despite treatment with typical doses of loop diuretics, including [
         <a href="#rid2">
          2-6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inadequate diuretic dose or frequency (see
         <a class="local">
          'Inadequate diuretic dose or frequency'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased intestinal absorption of oral diuretics (see
         <a class="local">
          'Decreased oral diuretic absorption'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased diuretic secretion into tubular fluid (see
         <a class="local">
          'Decreased loop diuretic tubular secretion'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased sodium reabsorption at sites in the nephron other than those inhibited by the diuretic (see
         <a class="local">
          'Enhanced tubular sodium reabsorption'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excess sodium intake (see
         <a class="local">
          'High salt intake'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concomitant administration of other classes of drugs that interfere with diuretic action (see
         <a class="local">
          'Drugs that interfere with diuretic action'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H465620961">
         <span class="h2">
          Inadequate diuretic dose or frequency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diuretics do not produce natriuresis until a threshold rate of drug excretion is attained (
         <a class="graphic graphic_figure graphicRef67654" href="/z/d/graphic/67654.html" rel="external">
          figure 1
         </a>
         ). If, for example, a patient does not respond to 40 mg of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         , the dose may not have exceeded this threshold. Thus, the single dose should be increased to 60 or 80 mg, rather than giving the 40 mg dose twice a day. Once a single effective dose has been determined, it is most commonly administered multiple times per day at a frequency that is individualized to the diuretic needs of the patient and the pharmacokinetic profile of the agent chosen. (See
         <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">
          "Loop diuretics: Dosing and major side effects"
         </a>
         .)
        </p>
        <p>
         Edematous patients are typically treated with one of the sulfonamide-based loop diuretics:
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">
          bumetanide
         </a>
         , or
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         . Each drug has a unique pharmacokinetic profile, although all three exert their predominant effect by blocking the Na-K-2Cl cotransporter at the luminal surface of thick ascending limb cells (
         <a class="graphic graphic_figure graphicRef75301" href="/z/d/graphic/75301.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">
          "Loop diuretics: Dosing and major side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2338.html" rel="external">
          "Mechanism of action of diuretics"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1641914902">
         <span class="h2">
          Decreased oral diuretic absorption
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with heart failure, decreased intestinal perfusion, reduced intestinal motility, and perhaps also mucosal edema can reduce the rate of diuretic absorption, and therefore reduce the rate of diuretic delivery into the tubular lumen by as much as 50 to 70 percent. This reduced delivery of diuretic into the renal tubule may keep it below the threshold [
         <a href="#rid7">
          7,8
         </a>
         ]. Thus, patients with acute decompensated heart failure typically require initial intravenous (IV) therapy.
        </p>
        <p>
         The defect in diuretic absorption is often reversible, resulting in more effective oral therapy following removal of some of the edema fluid with IV diuretics and stabilization of cardiac function [
         <a href="#rid7">
          7
         </a>
         ]. Similar considerations may apply to patients with advanced cirrhosis [
         <a href="#rid9">
          9
         </a>
         ], although some data suggest that
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         absorption is maintained in this setting and that the risks of IV treatment outweigh the benefits. (See
         <a class="medical medical_review" href="/z/d/html/1256.html" rel="external">
          "Ascites in adults with cirrhosis: Initial therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2047173185">
         <span class="h2">
          Decreased loop diuretic tubular secretion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Loop diuretics must enter the tubular fluid in order to exert their diuretic effect (
         <a class="graphic graphic_figure graphicRef75301" href="/z/d/graphic/75301.html" rel="external">
          figure 2
         </a>
         ). Loop diuretics are highly (≥95 percent) protein bound. As a result, they primarily enter the tubule lumen by secretion by the proximal tubule, not by glomerular filtration.
        </p>
        <p>
         Patients who do not respond to usual doses of loop diuretic therapy may be resistant because of decreased diuretic secretion into the tubular lumen. This may result from decreased kidney perfusion in patients with heart failure (due to the reduced cardiac output), cirrhosis (due to renal vasoconstriction), and kidney dysfunction (due to competitive inhibition of tubular diuretic secretion by high concentrations of organic anions that accumulate when the glomerular filtration rate is low). (See
         <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">
          "Loop diuretics: Dosing and major side effects"
         </a>
         .)
        </p>
        <p>
         Patients with nephrotic syndrome may also be unresponsive to diuretics due to decreased tubular secretion. Because loop diuretics are highly protein bound, severe hypoalbuminemia (&lt;2 g/dL) associated with the nephrotic syndrome may reduce the delivery of diuretic to the renal tubule. In addition, filtered albumin in nephrotic patients may bind loop diuretics in the tubular lumen, thereby interfering with their function. Proteases that are filtered in abnormal amounts in nephrotic patients may also activate epithelial sodium channels, thereby contributing to excess sodium retention [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3044.html" rel="external">
          "Pathophysiology and treatment of edema in adults with the nephrotic syndrome", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3129882009">
         <span class="h2">
          Enhanced tubular sodium reabsorption
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients have partial or relatively complete resistance to a loop diuretic despite adequate secretion of the diuretic into the tubular fluid (ie, despite having the same rate of urinary diuretic excretion as normal controls) (
         <a class="graphic graphic_figure graphicRef67654" href="/z/d/graphic/67654.html" rel="external">
          figure 1
         </a>
         ). This problem is often due to increased tubular sodium reabsorption by nephron segments other than the loop of Henle [
         <a href="#rid3">
          3,11,12
         </a>
         ]. The decreased response to the action of a diuretic that results from increased sodium reabsorption in other nephron segments has been called the diuretic braking phenomenon (
         <a class="graphic graphic_figure graphicRef122307" href="/z/d/graphic/122307.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         This phenomenon may be mediated by sodium reabsorption in various other nephron segments:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the proximal tubule, due to enhanced activity of angiotensin II and norepinephrine [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the distal tubule, due to flow-dependent hypertrophy resulting from chronic loop diuretic therapy, which increases sodium delivery and reabsorption at this thiazide-sensitive site (
         <a class="graphic graphic_figure graphicRef64975" href="/z/d/graphic/64975.html" rel="external">
          figure 4
         </a>
         ). The hypertrophy increases sodium reabsorption (
         <a class="graphic graphic_figure graphicRef53198" href="/z/d/graphic/53198.html" rel="external">
          figure 5
         </a>
         ) [
         <a href="#rid13">
          13,15
         </a>
         ]. Hypokalemia may also contribute to hypertrophy and increase the activity of the thiazide-sensitive Na-Cl cotransporter [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the collecting tubules, due to increased aldosterone (
         <a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">
          figure 6
         </a>
         ) [
         <a href="#rid4">
          4-6
         </a>
         ]. Additionally, filtered proteases in the settings of nephrotic syndrome, and perhaps heart failure, may cleave the epithelial sodium channel (ENaC), which increases its conductance for sodium [
         <a href="#rid10">
          10,18,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The neurohumoral activation occurs both as part of the primary disease (as in heart failure or cirrhosis) and as a consequence of diuretic-induced salt and water loss. One consequence of activating compensatory sodium-retaining mechanisms as soon as the extracellular fluid volume falls is that the maximum response to an IV diuretic occurs with the
         <strong>
          first dose
         </strong>
         , even with a continuous infusion, and the natriuresis begins to diminish within the first 12 hours (
         <a class="graphic graphic_figure graphicRef122307" href="/z/d/graphic/122307.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid3">
          3,20
         </a>
         ]. Similar findings are seen with oral diuretic therapy, assuming no defect in drug absorption. (See
         <a class="medical medical_review" href="/z/d/html/2356.html" rel="external">
          "Time course of loop and thiazide diuretic-induced electrolyte complications"
         </a>
         .)
        </p>
        <p>
         Two strategies may be helpful in overcoming the increase in sodium reabsorption in nephron segments not inhibited by the loop diuretic; the efficacy of either of these strategies is enhanced with concurrent sodium restriction since diuretics only
         <strong>
          transiently reverse
         </strong>
         the sodium-avid state and substantial sodium retention can occur when the diuretic effect wears off [
         <a href="#rid15">
          15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient has a partial but inadequate diuretic response to once-daily bolus therapy, the loop diuretic dose can be repeated twice or even three times a day. (See
         <a class="local">
          'Intensification of oral loop diuretic therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A second or third natriuretic agent can be added. (See
         <a class="local">
          'Combination oral diuretic therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2059508292">
         <span class="h2">
          High salt intake
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintenance of a high sodium intake can prevent net sodium loss and a reduction in extracellular fluid volume, even if there is an appropriate natriuretic response to diuretics.
        </p>
        <p>
         As the diuretic effect wanes, there is postdiuretic sodium retention due to the recovery of sodium reabsorption in the loop of Henle plus increased sodium reabsorption at other sites in the nephron [
         <a href="#rid12">
          12,21
         </a>
         ]. If sodium intake is high, postdiuretic sodium retention can counteract part or all of the natriuresis that occurred while the diuretic was active. The postdiuretic effect can be counteracted by dietary salt restriction. (See
         <a class="local">
          'Enhanced tubular sodium reabsorption'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3908247865">
         <span class="h2">
          Drugs that interfere with diuretic action
         </span>
         <span class="headingEndMark">
          —
         </span>
         Refractory edema may result from drugs that interfere with the action of diuretics. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsteroidal antiinflammatory drugs, which reduce the synthesis of vasodilator and natriuretic prostaglandins and impair diuretic responsiveness [
         <a href="#rid6">
          6,22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thiazolidinediones, such as
         <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">
          rosiglitazone
         </a>
         , increase renal salt retention as a result of upregulation of the ENaC in the collecting ducts and also increase proximal tubule sodium reabsorption [
         <a href="#rid23">
          23,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Fluid retention/heart failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H400109005">
         <span class="h1">
          MANAGEMENT OF REFRACTORY EDEMA
         </span>
        </p>
        <p class="headingAnchor" id="H97147636">
         <span class="h2">
          Pretreatment evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before intensifying diuretic therapy, the following steps should be taken:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclude excessive sodium intake – It is important to evaluate the patient's dietary sodium intake and attempt to reduce it, if excessive. To estimate sodium intake, a 24-hour urine should be collected. A value above 100 mmol in 24 hours (ie, 2.3 g of sodium) suggests that nonadherence with sodium restriction may be in part responsible for the resistance to diuretic therapy. (See
         <a class="local">
          'High salt intake'
         </a>
         above and
         <a class="medical medical_patient" href="/z/d/html/2181.html" rel="external">
          "Patient education: Collection of a 24-hour urine specimen (Beyond the Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A value above 100 to 120 mmol in 24 hours also suggests that the diuretic response is adequate since true diuretic resistance is manifested by intense renal sodium retention.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Confirm that the patient requires a reduction in extracellular fluid volume – While the mere presence of residual edema or pulmonary congestion (crackles or breathlessness) is suggestive, the decision to further reduce the extracellular fluid volume requires careful clinical judgement. As an example, a patient with pulmonary hypertension and heart failure with preserved systolic function may require a right-sided filling pressure that is elevated and associated with mild pedal edema to maintain sufficient left-sided function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         By contrast, in the setting of heart failure with reduced ejection fraction, more aggressive decongestion is usually needed, possibly guided by biomarkers such as brain natriuretic peptides or ultrasonographic assessment of the inferior vena cava [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2931922243">
         <span class="h2">
          Stepwise approach to refractory edema
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following approach is directed primarily to patients who have heart failure or substantially impaired kidney function. The management of refractory ascites in patients with liver disease and the management of edema in patients with nephrotic syndrome are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1258.html" rel="external">
          "Ascites in adults with cirrhosis: Diuretic-resistant ascites"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3044.html" rel="external">
          "Pathophysiology and treatment of edema in adults with the nephrotic syndrome"
         </a>
         .)
        </p>
        <p>
         Steps are provided in a progressively escalating order, although variations in the approach will be appropriate for specific patients. As an example, starting with intravenous (IV) therapy (rather than intensification of oral diuretics) is appropriate for acutely ill patients, such as those with acute decompensated heart failure.
        </p>
        <p>
         Our stepwise approach is similar to those successfully used in patients with acute decompensated heart failure and cardiorenal syndrome enrolled in the three randomized diuretic trials [
         <a href="#rid26">
          26,27
         </a>
         ], with a goal of attaining a daily diuresis of 3 to 5 liters per day until satisfactory decongestion occurs.
        </p>
        <p class="headingAnchor" id="H3481631196">
         <span class="h3">
          Intensification of oral loop diuretic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients can achieve adequate control of signs and symptoms of extracellular fluid volume expansion with typical diuretic doses given orally (
         <a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The following recommendations apply when this initial approach proves insufficient:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who do not have an adequate response to oral loop diuretic therapy should have the dose increased until either a clinically significant diuresis is attained or the maximum daily dose has been reached. (See
         <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">
          "Loop diuretics: Dosing and major side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Loop diuretics act rapidly, and therefore the patient should experience a notable increase in urine output within hours of an effective dose. If this does not occur, and especially if the body weight does not decline to indicate a reduction in extracellular volume, then doses can be escalated weekly, as long as adequate patient monitoring is available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When the diuretic response to oral loop diuretics is partial but inadequate (an increase in urine volume but little to no decrease in body weight), the net effect may be improved by repeating the same dose two or three times per day. Most guidelines suggest that, when initiating
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         therapy, it be given more than once daily.
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          Torsemide
         </a>
         , by contrast, is typically given daily, owing to its longer half-life. (See
         <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">
          "Loop diuretics: Dosing and major side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have not responded to a maximum effective oral dose of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         may have erratic or slowed gastrointestinal absorption of the drug. (See
         <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">
          "Loop diuretics: Dosing and major side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In such settings, it is reasonable to switch to oral
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         , which is more predictably absorbed and has a longer half-life than
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         or
         <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">
          bumetanide
         </a>
         [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients who do not have an adequate response to the maximum effective oral dose of
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         (100 to 200 mg per day in divided doses), an oral thiazide diuretic may be added to block distal reabsorption of sodium. (See
         <a class="local">
          'Combination oral diuretic therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H588577760">
         <span class="h3">
          Combination oral diuretic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         When an adequate response to loop diuretics is not obtained, concurrent administration of a thiazide-like (
         <a class="drug drug_general" data-topicid="9644" href="/z/d/drug information/9644.html" rel="external">
          metolazone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ) or thiazide-type (
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         ) diuretic to block distal sodium chloride reabsorption should be employed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients
         <strong>
          without hypokalemia
         </strong>
         , we typically add
         <a class="drug drug_general" data-topicid="9644" href="/z/d/drug information/9644.html" rel="external">
          metolazone
         </a>
         (5 mg once daily initially, increased to a maximum dose of 20 mg once daily) [
         <a href="#rid26">
          26
         </a>
         ], although
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         (25 to 50 mg twice daily initially, increased to a maximum dose of 200 mg per day) is likely just as effective [
         <a href="#rid30">
          30
         </a>
         ]. These drugs can produce a substantial additional diuresis when added to loop diuretics, even if kidney function is impaired [
         <a href="#rid30">
          30,31
         </a>
         ].
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          Chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         are other options, although supportive data are lacking. (See
         <a class="medical medical_review" href="/z/d/html/3871.html" rel="external">
          "Thiazides versus loop diuretics in the treatment of hypertension", section on 'Patients with chronic kidney disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The timing of combination therapy depends upon the route by which the diuretics are given. The drugs can be administered at the same time if given by the same route (IV or oral). If, however, a thiazide diuretic such as
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         is given orally in patients treated with an IV loop diuretic, the thiazide diuretic should precede the loop diuretic by two to five hours, since the peak effect of the thiazide is four to six hours after ingestion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Combination diuretic therapy can lead to a marked diuresis in which daily sodium and potassium losses can be greater than 300 mmol and 200 mmol, respectively [
         <a href="#rid31">
          31,32
         </a>
         ]. As a result, careful monitoring of fluid and electrolyte balance is essential when combination therapy is initiated (or when doses are changed). (See
         <a class="local">
          'Monitoring on therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, in
         <strong>
          hypokalemic patients
         </strong>
         , we generally add a potassium-sparing diuretic first (eg,
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         or, particularly in patients with heart failure, a mineralocorticoid receptor antagonist). Mineralocorticoid receptor antagonists were shown to be underutilized in a large study of patients who have heart failure with reduced ejection fraction, providing an opportunity for practice improvement [
         <a href="#rid33">
          33
         </a>
         ]. A thiazide-like or thiazide-type diuretic can then be added if the patient's edema remains refractory and hypokalemia has resolved.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We typically do not add
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         (a carbonic anhydrase inhibitor that blocks sodium reabsorption by the proximal tubule) unless the patient has severe metabolic alkalosis. Acetazolamide is less effective than thiazide-like and thiazide-type diuretics [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Sodium reabsorption can be blocked in the distal tubule by the concurrent administration of a thiazide-like or thiazide-type diuretic [
         <a href="#rid6">
          6,30,31,35
         </a>
         ]. The distal tubule reabsorbs approximately 75 to 80 percent of the sodium delivered out of the loop of Henle. Administration of a loop diuretic increases distal sodium delivery and, therefore, sodium reabsorption in the distal tubule, an effect mediated in part by increased activity of the thiazide-sensitive Na-Cl cotransporter in the luminal membrane of the distal tubule cells [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         The efficacy of adding a thiazide diuretic was illustrated in a study of five patients who had an inadequate response to
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         in doses of 160 to 240 mg per day (given in divided doses three to four times daily) [
         <a href="#rid30">
          30
         </a>
         ]. All had significant chronic kidney disease (CKD) with a serum creatinine ranging from 2.3 to 4.9 mg/dL (203 to 433 micromol/L). Increasing the furosemide dose to 320 to 480 mg/day produced only a modest increase in urine output. By contrast, the addition of
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         (25 to 50 mg twice daily) was associated with a marked diuresis and a significant reduction in weight.
        </p>
        <p>
         Many experts use
         <a class="drug drug_general" data-topicid="9644" href="/z/d/drug information/9644.html" rel="external">
          metolazone
         </a>
         as the oral thiazide diuretic of choice in patients with refractory edema and advanced kidney disease (ie, glomerular filtration rate [GFR] below 20 mL/min) since other thiazide-type drugs were thought to be ineffective in this setting [
         <a href="#rid36">
          36
         </a>
         ]. However, the study that produced this conclusion used extremely high doses of metolazone (20 to 150 mg, the equivalent of 200 to 1500 mg of
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         ). Thus, there is no convincing evidence that metolazone is superior to comparable doses of other thiazides, although it, like
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         , does have the advantage of once-daily dosing [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Potassium-sparing diuretics, such as mineralocorticoid receptor antagonists and
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         , can help limit potassium wasting, although data demonstrating their efficacy in reducing extracellular fluid volume are limited [
         <a href="#rid10">
          10,37
         </a>
         ]. In one study, for example, high-dose
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         (100 mg per day compared with placebo or low-dose spironolactone) did not improve clinical congestion score, increase urine output, or reduce body weight in patients hospitalized for acute heart failure who were receiving IV loop diuretics [
         <a href="#rid37">
          37
         </a>
         ]. However, these results, plus the finding that the serum potassium did not increase, may be explained by the fact that patients were followed for only 96 hours, and the onset of action of spironolactone may be slow.
        </p>
        <p class="headingAnchor" id="H4153306906">
         <span class="h3">
          Intravenous loop diuretic bolus therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute decompensated heart failure and hospitalized patients with refractory edema are typically treated with IV loop diuretics. The following represents our general approach in such patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The initial dose of IV loop diuretic should be approximately 2 or 2.5 times the patient's home oral dose (eg, a patient taking 40 mg of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         orally twice daily at home can be given 80 mg of IV furosemide as an initial bolus) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one large diuretic trial, IV loop diuretics given at 2.5 times the home daily dose were safe for patients with acute decompensated heart failure and exhibited modestly better outcomes than an IV dose equivalent to the home dose [
         <a href="#rid39">
          39
         </a>
         ]. In addition, the Heart Failure Association of the European Society of Cardiology (ESC) suggests initiating IV dosing at one to two times the home daily dose [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If there is little or no response to the initial dose, the dose should be doubled at two-hour intervals, as needed, up to the maximum recommended doses (
         <a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">
          table 1
         </a>
         ) rather than repeated at the same dose. As an example, if an 80 mg IV
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         dose does not produce an adequate diuresis within two hours, then a 160 mg IV dose should be given. Repeated administration of the same, ineffective IV dose is unlikely to increase efficacy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It should be noted that doses higher than the "maximum effective dose" often produce further diuresis, albeit with less sodium excretion per milligram of diuretic administered. This is because the plasma diuretic concentration remains above the diuretic threshold for a longer period of time. Some evidence-based guidelines for the treatment of refractory edema recommend doses above the maximum effective dose. Yet, they may also increase the risk of side effects. (See
         <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">
          "Loop diuretics: Dosing and major side effects", section on 'Maximum effective doses'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who do not have an adequate response to a maximal dose of one IV loop diuretic are unlikely to respond to another loop diuretic since their mechanisms of action are similar. In contrast to the potential benefit derived from switching oral
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         to an alternative
         <strong>
          oral
         </strong>
         loop diuretic, there is no benefit from switching to an alternative
         <strong>
          IV
         </strong>
         loop diuretic. The higher efficacy of oral
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         compared with oral furosemide results from differences in oral bioavailability. There is no such difference in bioavailability when the route of administration is IV. (See
         <a class="local">
          'Intensification of oral loop diuretic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loop diuretics should not be administered IV as a rapid "push." Bolus IV
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         doses of 160 to 200 mg (and equivalent doses of
         <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">
          bumetanide
         </a>
         and
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         ) occasionally cause transient tinnitus. This effect can be minimized by giving the dose more slowly [
         <a href="#rid3">
          3
         </a>
         ]. Ototoxicity is most common when high doses of a loop diuretic are given rapidly at rates for furosemide above 4 mg/min.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who fail to respond to maximal IV bolus doses of a loop diuretic, a thiazide-like or thiazide-type diuretic can be coadministered.
         <a class="drug drug_general" data-topicid="9248" href="/z/d/drug information/9248.html" rel="external">
          Chlorothiazide
         </a>
         is the only thiazide diuretic that can be given IV (500 to 1000 mg once or twice daily) [
         <a href="#rid42">
          42
         </a>
         ]. However, the availability of IV chlorothiazide may be limited. An oral preparation, such as
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         or
         <a class="drug drug_general" data-topicid="9644" href="/z/d/drug information/9644.html" rel="external">
          metolazone
         </a>
         , is an alternative for acute therapy and can be used chronically. In a retrospective analysis, oral metolazone appeared to be as effective as IV chlorothiazide, suggesting that this agent should be chosen unless the patient cannot take medications by mouth [
         <a href="#rid43">
          43
         </a>
         ]. As noted above, if an oral thiazide (such as metolazone) is combined with an IV loop diuretic, the metolazone should be given two to five hours before infusion of the loop diuretic.
        </p>
        <p>
        </p>
        <p>
         Resistance to oral diuretics is frequently reversible, and therefore, oral diuretic therapy may become more effective following removal of some of the edema fluid with IV diuretics. Thus, patients who are treated with an IV diuretic following failure of oral therapy can be given a repeat trial of oral diuretics once the hypervolemia has improved. (See
         <a class="local">
          'Conversion to oral treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3565437700">
         <span class="h4">
          Continuous infusion option in patients who respond to bolus therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with refractory edema who respond to an IV bolus of a loop diuretic but need ongoing diuresis, we frequently initiate a continuous loop diuretic infusion. Continuous diuretic therapy may be less ototoxic than bolus therapy and maintains a sustained effective rate of diuretic excretion. A continuous infusion should
         <strong>
          only
         </strong>
         be used in patients who are first responsive to bolus loop diuretic therapy. Bolus therapy results in higher initial serum diuretic concentrations and, therefore, higher initial rates of urinary diuretic excretion than a continuous infusion [
         <a href="#rid44">
          44
         </a>
         ]. Thus, in patients who fail to respond to the maximal bolus doses described above, continuous infusion will be ineffective.
        </p>
        <p>
         Our approach to continuous infusion of loop diuretics is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An IV loading dose of 40 to 80 mg of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         is typically given over five minutes prior to initiating the continuous infusion. If the patient has received one or more IV boluses within the previous few hours, then an infusion can be started without a loading dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After the loading dose, the starting infusion rate with
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         varies with the level of kidney function:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the patient has severe kidney impairment (acute kidney injury or CKD with an estimated GFR [eGFR] less than 30 mL/min per 1.73 m
         <sup>
          2
         </sup>
         ), we use an initial
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         infusion rate of 20 mg per hour. If the diuresis is not sustained, a second bolus is given followed by a higher infusion rate of 40 mg per hour. The equivalent dose is 1 mg per hour, increasing to 2 mg per hour for
         <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">
          bumetanide
         </a>
         , and 10 mg per hour, increasing to 20 mg per hour for
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the patient has an eGFR greater than or equal to 30 mL/min per 1.73 m
         <sup>
          2
         </sup>
         , we use an initial
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         infusion rate of 5 mg per hour. If the diuresis is not sustained, a second bolus is given followed by a higher infusion rate of 10 mg per hour. This rate may then be increased further to the maximum recommended furosemide infusion rate of 40 mg per hour if response to lower doses is poor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher infusion rates of up to 240 mg per hour are reported in the literature. However, we do not recommend these higher doses. The risk of ototoxicity and other side effects associated with these infusion rates must be weighed against alternative strategies, such as the addition of a thiazide diuretic or fluid removal via ultrafiltration, as described below. (See
         <a class="local">
          'Patients unresponsive to intravenous diuretics'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The physiologic rationale for a continuous IV infusion compared with bolus therapy is related to maintenance of an effective rate of drug excretion and, therefore, inhibition of sodium chloride reabsorption in the loop of Henle over time (
         <a class="graphic graphic_figure graphicRef67654" href="/z/d/graphic/67654.html" rel="external">
          figure 1
         </a>
         ). By contrast, bolus therapy is associated with initially higher and then lower rates of diuretic excretion; as a result, sodium excretion may be at near maximal levels for the first two hours but then gradually falls until the next dose is given (
         <a class="graphic graphic_figure graphicRef122307" href="/z/d/graphic/122307.html" rel="external">
          figure 3
         </a>
         ).
        </p>
        <p>
         The efficacy of a continuous IV infusion compared with IV bolus therapy has been evaluated in randomized trials [
         <a href="#rid20">
          20,26,39,45
         </a>
         ]. A continuous IV infusion is associated with less ototoxicity than bolus injections of loop diuretics, but clear evidence of greater diuretic efficacy is lacking, at least in patients with acute decompensated heart failure. The following observations illustrate the range of findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a systematic review of eight trials that included 254 patients with acute heart failure, continuous infusion led to a modestly higher urine output at 24 hours (mean difference 271 mL) [
         <a href="#rid46">
          46
         </a>
         ]. In addition, ototoxicity was less frequent in patients receiving continuous therapy. However, the apparent benefit on urine output was largely driven by a trial of 107 patients in which patients given continuous therapy also received hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The best data come from the DOSE trial, which was published after the aforementioned meta-analysis [
         <a href="#rid39">
          39
         </a>
         ]. In this trial, 308 patients with acute heart failure were randomly assigned to receive bolus IV
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         every 12 hours or continuous infusion, and also to either low-dose (equivalent to the patient's previous oral dose) or high-dose (2.5 times the previous oral dose) diuretics. At 72 hours, the following findings were noted:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Continuous and bolus therapy resulted in similar degrees of symptom improvement and fluid loss. However, the continuous regimen did not include an initial bolus of diuretic, which is typically recommended, and the dose of continuous infusion was not escalated in a manner similar to that recommended in most guidelines (
         <a class="graphic graphic_table graphicRef121128" href="/z/d/graphic/121128.html" rel="external">
          table 2
         </a>
         ). In addition, patients assigned bolus therapy required dose escalation and, therefore, higher total
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         doses (592 versus 480 mg, although this was not statistically different). Bolus therapy also led to nonsignificantly higher rates of ventricular tachycardia and myocardial infarction.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High-dose as compared with low-dose
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         produced greater net fluid loss, weight loss, and relief from dyspnea, but also more frequent worsening of kidney function (23 versus 14 percent). However, in this and some other trials, a rise in creatinine was not associated with worse long-term outcomes provided that the patients were decongested [
         <a href="#rid47">
          47
         </a>
         ]. Thus, because modest rises in creatinine are not typically associated with tubule injury [
         <a href="#rid48">
          48
         </a>
         ], they should not lead to a reduction in dose, as long as diuresis is successful. (See
         <a class="local">
          'Decongestion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H349388904">
         <span class="h4">
          Patients unresponsive to intravenous diuretics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with advanced heart failure and kidney impairment do not respond to or cannot tolerate maximal loop diuretic doses given IV in combination with thiazide diuretics. In this setting, the excess fluid can be removed by ultrafiltration during kidney replacement therapy. (See
         <a class="medical medical_review" href="/z/d/html/1845.html" rel="external">
          "Continuous kidney replacement therapy in acute kidney injury", section on 'Slow continuous ultrafiltration (SCUF)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1845.html" rel="external">
          "Continuous kidney replacement therapy in acute kidney injury", section on 'Continuous venovenous hemofiltration (CVVH)'
         </a>
         .)
        </p>
        <p>
         Kidney replacement therapy is generally reserved for patients with substantial cardiorenal dysfunction who require concomitant dialysis or in patients enrolled in clinical trials.
        </p>
        <p class="headingAnchor" id="H3326613236">
         <span class="h2">
          Benefit from a supine posture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diuretic responsiveness can be influenced by posture, although the effects of posture have not been specifically studied in patients with refractory edema. Patients with heart failure, for example, cannot increase cardiac output normally with assumption of an upright position. As a result, kidney perfusion and presumably urinary diuretic delivery further diminish. In addition, renal salt and water reabsorption increase.
        </p>
        <p>
         The efficacy of assuming a supine position was evaluated in a randomized trial of six patients with heart failure and six with cirrhosis and ascites [
         <a href="#rid49">
          49
         </a>
         ]. After staying in bed overnight, the patients were treated with 1 mg of
         <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">
          bumetanide
         </a>
         IV and then assigned to either continued bed rest or normal daily activity for the next six hours. The procedure was repeated two days later when each patient was assigned to the opposite group. The supine position was associated with higher mean creatinine clearance (100 versus 66 mL/min) and diuretic response (1133 versus 626 mL at six hours). The upright position was associated with significant increases in plasma norepinephrine, renin, and aldosterone.
        </p>
        <p class="headingAnchor" id="H2580705958">
         <span class="h2">
          Monitoring on therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The need to monitor clinical and laboratory parameters varies depending upon the clinical scenario. For stable patients on maintenance diuretics, clinical status, serum electrolytes, and creatinine are assessed during routine clinical visits.
        </p>
        <p>
         However, when diuretic therapy is being intensified to reduce the extracellular fluid volume, these parameters should be monitored frequently (weekly, for example) until stable, satisfactory doses of diuretics are attained. Frequent monitoring, at least initially, is often recommended for patients being discharged after a hospitalization for acute heart failure. In addition to daily weight monitoring, many heart failure programs provide specific advice on diuretic dosing and the need for laboratory testing.
        </p>
        <p>
         Worsening kidney function is observed commonly during diuretic treatment and has been associated with worse outcomes [
         <a href="#rid50">
          50
         </a>
         ]. For this reason, worsening kidney function, typically defined as an increase in plasma creatinine concentration &gt;0.3 mg/dL (26.5 micromol/L), is frequently used as a harm signal in large clinical trials [
         <a href="#rid39">
          39
         </a>
         ]. Yet, post hoc analyses of such trials have indicated that this association is not necessarily causal and may be response dependent. In the DOSE study, for example, worsening kidney function was not associated with poorer prognosis [
         <a href="#rid47">
          47
         </a>
         ]. In addition, in the ROSE-AHF trial, changes in creatinine did not indicate kidney injury, as manifested by a lack of injury biomarkers [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
         Some evidence suggests that the state of decongestion during diuretic treatment is a major determinant of prognosis in the setting of worsening kidney function; worsening kidney function may be viewed as an adverse effect when decongestion is incomplete (the patient remains resistant to diuretics) but not when an acceptable diuretic response has been attained.
        </p>
        <p class="headingAnchor" id="H3363616358">
         <span class="h2">
          Goals of therapy
         </span>
        </p>
        <p class="headingAnchor" id="H2863160945">
         <span class="h3">
          Decongestion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The desired response to diuresis is determined by the severity of extracellular fluid volume overload and the clinical scenario. In the setting of acute decompensated heart failure, many authorities suggest relatively rapid decongestion (3 to 4 or 3 to 5 liters per day) and a goal of complete decongestion, as persistent congestion has been associated with worse outcomes [
         <a href="#rid27">
          27,41
         </a>
         ]. It should be noted, however, that these associations have been determined retrospectively, and prospective data dictating the role of persistent extracellular fluid volume expansion in prognosis are lacking.
        </p>
        <p>
         As noted, it is difficult to recommend a single approach to estimate congestion. An algorithm endorsed by the Heart Failure Association of the ESC provides some guidance (
         <a class="graphic graphic_figure graphicRef120693" href="/z/d/graphic/120693.html" rel="external">
          figure 7
         </a>
         ) [
         <a href="#rid41">
          41
         </a>
         ]. Yet, it should be emphasized that this approach has not been validated in prospective randomized trials.
        </p>
        <p class="headingAnchor" id="H2798021739">
         <span class="h3">
          Conversion to oral treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hospitalized patients are typically considered ready for discharge once they have been stable for 24 hours on oral therapy. It is often recommended to double the
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         dose when switching from IV to oral administration since the mean bioavailability is only approximately 50 percent. There is substantial interpatient and intrapatient variability in the bioavailability of oral furosemide, however, making it difficult to give a fixed ratio that would apply to all patients, and the Heart Failure Association of the ESC suggests starting with the same oral dose as was used IV [
         <a href="#rid41">
          41
         </a>
         ]. In our practice, we typically substitute an oral dose that is between 1 and 1.5 times the IV dose and then monitor urine output to determine its effectiveness.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of normal volunteers, a single oral dose of 40 mg produced the same natriuretic effect as an IV dose of 40 mg; in this case, the peak serum concentration was higher with the IV dose, but the duration above the diuretic threshold was longer with oral dosing [
         <a href="#rid51">
          51
         </a>
         ]. In outpatients, the efficacy of therapy can be monitored by having daily weights called into the clinician's office or monitored electronically.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IV and oral doses are similar in patients treated with
         <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">
          bumetanide
         </a>
         or
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         , which have higher rates of oral bioavailability than
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         (70 to 95 percent and 80 to 90 percent, respectively). Careful monitoring is still required since there is substantial variability in response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More important than specific arbitrary dosing guidelines, however, is the need for early follow-up. A reassessment of weight, physical examination, and laboratory measurements is recommended within two weeks of discharge.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1135058915">
         <span class="h1">
          STRATEGIES WE DO NOT USE
         </span>
        </p>
        <p class="headingAnchor" id="H1656796112">
         <span class="h2">
          Renal dose dopamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although some small, lower-quality studies suggested a benefit from low-dose
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         , a larger, high-quality trial found no benefit and potential harm; therefore, low-dose dopamine cannot be recommended.
        </p>
        <p>
         The addition of low-dose
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         (or alternatively,
         <a class="drug drug_general" data-topicid="10128" href="/z/d/drug information/10128.html" rel="external">
          nesiritide
         </a>
         ) in the setting of acute decompensated heart failure was examined in 360 patients in the large randomized ROSE-HF trial [
         <a href="#rid45">
          45
         </a>
         ]. The addition of low-dose dopamine did not significantly increase urine volume or improve decongestion compared with placebo, although it did increase the incidence of arrhythmias.
        </p>
        <p class="headingAnchor" id="H274057556">
         <span class="h2">
          Albumin infusion for hypoalbuminemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with hypoalbuminemia are relatively resistant to conventional diuretic therapy. It has been proposed that these patients may respond to the administration of 40 to 80 mg of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         mixed with 6.25 to 12.5 g of salt-poor albumin. Infusion of the furosemide-albumin complex is thought to increase diuretic delivery to the kidney by keeping furosemide within the vascular space. In a small initial report, this approach led to a substantial increase in sodium excretion in some patients [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         However, a subsequent study in patients with nephrotic syndrome (mean plasma albumin 3.0 g/dL) found that a mixture of loop diuretic and albumin (60 mg of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         infused in 200 mL of a 20 percent
         <a class="drug drug_general" data-topicid="9376" href="/z/d/drug information/9376.html" rel="external">
          albumin solution
         </a>
         ) produced only a modest increase in sodium excretion compared with furosemide alone, without an increase in the rate of furosemide excretion [
         <a href="#rid53">
          53
         </a>
         ]. In addition, the increase in sodium excretion was roughly equivalent to the amount of sodium contained in the colloid solution, suggesting that volume expansion was a likely explanation for the enhanced natriuresis. Notably, no net sodium loss occurred.
        </p>
        <p>
         A similar lack of efficacy of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         plus albumin infusion has been demonstrated in hypoalbuminemic patients with cirrhosis (mean plasma albumin 3.0 g/dL) [
         <a href="#rid54">
          54
         </a>
         ]. Compared with furosemide alone, combination therapy did not increase the rate of either furosemide or sodium excretion.
        </p>
        <p>
         Few patients with severe hypoalbuminemia (plasma albumin &lt;2.0 g/dL) have been studied. It is possible that infusion of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         or other loop diuretics plus albumin would be effective in patients with refractory edema and severe hypoalbuminemia. However, if attempted, sodium excretion should be monitored after addition of albumin infusions, and infusions should be discontinued if they do not result in a net increase in sodium excretion. General issues related to the management of edema in patients with nephrotic syndrome are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3044.html" rel="external">
          "Pathophysiology and treatment of edema in adults with the nephrotic syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3584468428">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">
          "Society guideline links: Fluid and electrolyte disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4413.html" rel="external">
          "Patient education: Edema (swelling) (Beyond the Basics)"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17558105">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Refractory edema is defined as edema that is persistent despite the use of typically effective doses of loop diuretics. While this definition appears to be straightforward, it is often difficult to determine the optimal extracellular fluid volume status for an edematous patient, as this process involves substantial clinical judgement and shared decision-making. (See
         <a class="local">
          'Definition of refractory edema'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A variety of factors can account for persistent sodium and water retention, despite treatment with typical doses of loop diuretics, including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inadequate diuretic dose or frequency (see
         <a class="local">
          'Inadequate diuretic dose or frequency'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Decreased intestinal absorption of oral diuretics (see
         <a class="local">
          'Decreased oral diuretic absorption'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Decreased diuretic secretion into tubular fluid (see
         <a class="local">
          'Decreased loop diuretic tubular secretion'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increased sodium reabsorption at sites in the nephron other than those inhibited by the diuretic (see
         <a class="local">
          'Enhanced tubular sodium reabsorption'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Excess sodium intake (see
         <a class="local">
          'High salt intake'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Concomitant administration of other classes of drugs that interfere with diuretic action (see
         <a class="local">
          'Drugs that interfere with diuretic action'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Before intensifying diuretic therapy in patients at steady state, excessive sodium intake (a value above 100 mmol in 24 hours) should be excluded, and it should be confirmed that the patient requires a reduction in extracellular fluid volume. (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The following approach is directed primarily to patients who have heart failure or substantially impaired kidney function; the management of refractory ascites in patients with liver disease and the management of edema in patients with nephrotic syndrome are presented elsewhere (see
         <a class="medical medical_review" href="/z/d/html/1258.html" rel="external">
          "Ascites in adults with cirrhosis: Diuretic-resistant ascites"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3044.html" rel="external">
          "Pathophysiology and treatment of edema in adults with the nephrotic syndrome"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who do not have an adequate response to oral loop diuretic therapy should have the dose increased until either a clinically significant diuresis is attained or the maximum daily dose has been reached (
         <a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">
          table 1
         </a>
         ). In patients who have not responded to a maximum effective oral dose of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         , it is reasonable to switch to oral
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         . (See
         <a class="local">
          'Intensification of oral loop diuretic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When an adequate response to loop diuretics is not obtained, concurrent administration of a thiazide-like (
         <a class="drug drug_general" data-topicid="9644" href="/z/d/drug information/9644.html" rel="external">
          metolazone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ) or thiazide-type (
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         ) diuretic to block distal sodium chloride reabsorption should be employed. However, in hypokalemic patients, we generally add a potassium-sparing diuretic first. A thiazide-like or thiazide-type diuretic can then be added if the patient's edema remains refractory and hypokalemia has resolved. (See
         <a class="local">
          'Combination oral diuretic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with acute decompensated heart failure and hospitalized patients with refractory edema are typically treated with intravenous (IV) loop diuretics. The following represents our general approach in such patients (see
         <a class="local">
          'Intravenous loop diuretic bolus therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The initial dose of IV loop diuretic should be approximately 2 or 2.5 times the patient's maintenance oral dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If there is little or no response to the initial dose, the dose should be doubled at two-hour intervals, as needed, up to the maximum recommended doses (
         <a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">
          table 1
         </a>
         ) rather than repeated at the same dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In patients who fail to respond to maximal IV bolus doses of a loop diuretic, a thiazide-like or thiazide-type diuretic can be coadministered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with refractory edema who respond to an IV bolus of a loop diuretic but need ongoing diuresis, we frequently initiate a continuous loop diuretic infusion. Continuous diuretic therapy may be less ototoxic than bolus therapy and maintains a sustained effective rate of diuretic excretion. A continuous infusion should
         <strong>
          only
         </strong>
         be used in patients who are first responsive to bolus loop diuretic therapy. (See
         <a class="local">
          'Continuous infusion option in patients who respond to bolus therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some patients with advanced heart failure and kidney impairment do not respond to or cannot tolerate maximal loop diuretic doses given IV in combination with thiazide diuretics. In this setting, the excess fluid can be removed by ultrafiltration during kidney replacement therapy. (See
         <a class="local">
          'Patients unresponsive to intravenous diuretics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hospitalized patients are typically considered ready for discharge once they have been stable for 24 hours on oral therapy. In our practice, we typically substitute an oral dose that is between 1 and 1.5 times the IV dose and then monitor urine output to determine its effectiveness. (See
         <a class="local">
          'Conversion to oral treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hoorn EJ, Ellison DH. Diuretic Resistance. Am J Kidney Dis 2017; 69:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellison DH. Mechanistic Insights into Loop Diuretic Responsiveness in Heart Failure. Clin J Am Soc Nephrol 2019; 14:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brater DC. Diuretic therapy. N Engl J Med 1998; 339:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose BD. Diuretics. Kidney Int 1991; 39:336.
          </a>
         </li>
         <li class="breakAll">
          Brater DC, Voelker JR. Use of diuretics in patients with renal disease. In: Pharmacotherapy of Renal Disease and Hypertension (Contemporary Issues in Nephrology), Bennett WM, McCarron DA (Eds), Churchill Livingstone, New York 1987. Vol 17.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellison DH. Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am J Kidney Dis 1994; 23:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krämer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med 1999; 106:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fredrick MJ, Pound DC, Hall SD, Brater DC. Furosemide absorption in patients with cirrhosis. Clin Pharmacol Ther 1991; 49:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohnert BN, Menacher M, Janessa A, et al. Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome. Kidney Int 2018; 93:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao VS, Planavsky N, Hanberg JS, et al. Compensatory Distal Reabsorption Drives Diuretic Resistance in Human Heart Failure. J Am Soc Nephrol 2017; 28:3414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989; 36:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald H, Scherzer P, Popovtzer MM. Na,K-ATPase in isolated nephron segments in rats with experimental heart failure. Circ Res 1991; 68:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volume-independent component to postdiuretic sodium retention in humans. J Am Soc Nephrol 1993; 3:1878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saritas T, Puelles VG, Su XT, et al. Optical Clearing in the Kidney Reveals Potassium-Mediated Tubule Remodeling. Cell Rep 2018; 25:2668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terker AS, Zhang C, McCormick JA, et al. Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride. Cell Metab 2015; 21:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng H, Liu X, Sharma NM, et al. Urinary Proteolytic Activation of Renal Epithelial Na+ Channels in Chronic Heart Failure. Hypertension 2016; 67:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svenningsen P, Friis UG, Versland JB, et al. Mechanisms of renal NaCl retention in proteinuric disease. Acta Physiol (Oxf) 2013; 207:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991; 115:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 1983; 102:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brater DC. Analysis of the effect of indomethacin on the response to furosemide in man: effect of dose of furosemide. J Pharmacol Exp Ther 1979; 210:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fu Y, Gerasimova M, Batz F, et al. PPARγ agonist-induced fluid retention depends on αENaC expression in connecting tubules. Nephron 2015; 129:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horita S, Nakamura M, Satoh N, et al. Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention. PPAR Res 2015; 2015:646423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaptein MJ, Kaptein EM. Focused Real-Time Ultrasonography for Nephrologists. Int J Nephrol 2017; 2017:3756857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367:2296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grodin JL, Stevens SR, de Las Fuentes L, et al. Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. J Card Fail 2016; 22:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah P, Patel H, Mithawala P, Doshi R. Torsemide versus furosemide in heart failure patients: A meta-analysis of randomized controlled trials. Eur J Intern Med 2018; 57:e38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah S, Pitt B, Brater DC, et al. Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action. J Am Heart Assoc 2017; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med 1982; 72:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fliser D, Schröter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oster JR, Epstein M, Smoller S. Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983; 99:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira JP, Rossignol P, Machu JL, et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. Eur J Heart Fail 2017; 19:1284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kassamali R, Sica DA. Acetazolamide: a forgotten diuretic agent. Cardiol Rev 2011; 19:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdallah JG, Schrier RW, Edelstein C, et al. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol 2001; 12:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dargie HJ, Allison ME, Kennedy AC, Gray MJ. High dosage metolazone in chronic renal failure. Br Med J 1972; 4:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler J, Anstrom KJ, Felker GM, et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol 2017; 2:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felker GM, Ellison DH, Mullens W, et al. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 75:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullens W, Verbrugge FH, Nijst P, et al. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail 2018; 20:1591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaud CJ, Mintus KC. Intravenous Chlorothiazide Versus Enteral Metolazone to Augment Loop Diuretic Therapy in the Intensive Care Unit. Ann Pharmacother 2017; 51:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013; 310:2533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005; :CD003178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brisco MA, Zile MR, Hanberg JS, et al. Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. J Card Fail 2016; 22:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmad T, Jackson K, Rao VS, et al. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. Circulation 2018; 137:2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ring-Larsen H, Henriksen JH, Wilken C, et al. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J (Clin Res Ed) 1986; 292:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014; 35:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982; 22:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987; 32:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fliser D, Zurbrüggen I, Mutschler E, et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int 1999; 55:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalasani N, Gorski JC, Horlander JC Sr, et al. Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 2001; 12:1010.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2324 Version 39.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27814935" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Diuretic Resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31064772" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Mechanistic Insights into Loop Diuretic Responsiveness in Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9691107" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Diuretic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2002648" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Diuretics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2002648" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Diuretics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8172204" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Diuretic drugs and the treatment of edema: from clinic to bench and back again.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6503136" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Bumetanide and furosemide in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10320123" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Diuretic treatment and diuretic resistance in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2007318" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Furosemide absorption in patients with cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29042083" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28739647" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Compensatory Distal Reabsorption Drives Diuretic Resistance in Human Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2014951" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The physiologic basis of diuretic synergism: its role in treating diuretic resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2811065" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Mechanism of impaired natriuretic response to furosemide during prolonged therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1849057" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Na,K-ATPase in isolated nephron segments in rats with experimental heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8338919" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A volume-independent component to postdiuretic sodium retention in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30517856" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Optical Clearing in the Kidney Reveals Potassium-Mediated Tubule Remodeling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25565204" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26628676" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Urinary Proteolytic Activation of Renal Epithelial Na+ Channels in Chronic Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23216619" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mechanisms of renal NaCl retention in proteinuric disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1863026" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6886524" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Response of the kidney to furosemide. I. Effects of salt intake and renal compensation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/480189" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Analysis of the effect of indomethacin on the response to furosemide in man: effect of dose of furosemide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25531136" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : PPARγagonist-induced fluid retention depends onαENaC expression in connecting tubules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26074951" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28261499" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Focused Real-Time Ultrasonography for Nephrologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23131078" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Ultrafiltration in decompensated heart failure with cardiorenal syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26209004" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30177487" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Torsemide versus furosemide in heart failure patients: A meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28982672" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7046434" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7967362" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6614693" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28580625" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21983315" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Acetazolamide: a forgotten diuretic agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11423562" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5082545" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : High dosage metolazone in chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28700781" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32164892" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21366472" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Diuretic strategies in patients with acute decompensated heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30238574" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30600580" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23747642" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28228057" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Intravenous Chlorothiazide Versus Enteral Metolazone to Augment Loop Diuretic Therapy in the Intensive Care Unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8800113" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24247300" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16034890" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Continuous infusion versus bolus injection of loop diuretics in congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27374839" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29352071" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3085844" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24164864" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7120755" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The time course of delivery of furosemide into urine: an independent determinant of overall response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3656933" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9987087" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Coadministration of albumin and furosemide in patients with the nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11316860" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
